ProMIS Neurosciences

ProMIS is focused on development of antibody therapeutics targeting toxic proteins implicated in Alzheimer’s, ALS and multiple system atrophy. NASDAQ:PMN

[ProMIS Neurosciences @ProMISinc]

This June, ProMIS CEO, Neil Warma, will participate in several conferences to discuss our EpiSelect™ platform and lead Alzheimer’s disease candidate, PMN310, as we approach our PRECISE-AD blinded interim data analysis in early Q3 2026. Learn more: https://t.co/NDAwrHVtMT

[ProMIS Neurosciences @ProMISinc]

Are you attending @LifeSciEvents' #FierceBiotechWeek 2026? Our CEO, Neil Warma, will moderate a panel on the future of neurodegenerative drug development, including combination strategies & earlier intervention. Learn more about the panel here: https://t.co/yQsNrwejpZ
#FBW2026

[ProMIS Neurosciences @ProMISinc]

Today, we announced our Q1 2026 financial results and corporate highlights. Read more in our press release: https://t.co/uz87nLrUMW

[ProMIS Neurosciences @ProMISinc]

Neurology Today and ANN, thank you for the opportunity to discuss science. Dr. Kaplan said the Abeta vaccine differs from other development because it “is selective for toxic oligomers and does not contain Abeta T-cell epitopes, so it will not stimulate detrimental T cells."

[Neurology Today @NeurologyToday]

Via #AANAM: A vaccine targeting abeta oligomers to inhibit progression of #Alzheimers disease produced a strong antibody response in mice without inducing any measurable inflammatory response: https://t.co/8xzaU7swVf

#neurotwitter #dementia @AANMember @ProMISinc @TWisniewskiMD

[ProMIS Neurosciences @ProMISinc]

Antibodies that bind selectively to neurotoxic Aβ oligomers potentially  modify the course of the Alzheimer's disease. https://t.co/4FPtpsRmHg

[ProMIS Neurosciences @ProMISinc]

On Nov 14th we shared third quarter 2022 financial results and highlighted recent developments. https://t.co/gKQvvCdYXO
#Alzheimers #ENDALZ $PMN

[ProMIS Neurosciences @ProMISinc]

@Roche's gantenerumab and will deliver phase 3 results this year. PMN310 is a next-generation candidate that can target toxic Aß with greater precision. https://t.co/N0A8KGqbXh #ENDALZ #Pharmaceuticals #biotech

[ProMIS Neurosciences @ProMISinc]

Our #drugdiscovery platform combines #biology, #physics and #supercomputing to neutralize toxic amyloid with a precision that traditional #drugdevelopment tools can't achieve. Data show no monomer distraction. https://t.co/CVWyKX1dqW #TechTuesday #biotech #ENDALZ

[ProMIS Neurosciences @ProMISinc]

ProMIS has an important point of #differentiation. Our platform enables us to develop #antibodies that are highly selective for toxic misfolded #proteins. #Physics + #Biology + #Supercomputing.
$PMN #differentiated #toxicoligomers #misfoldedproteins #neurodegenerativedisease

[ProMIS Neurosciences @ProMISinc]

"Antibodies that target amyloid latch on at slightly different places.” #Lecanemab binds to protofibrils. “...before these chains clump together to form plaques in the brain. It could be that catching the amyloid earlier in the process makes a difference." https://t.co/rFByEm7Eel

[ProMIS Neurosciences @ProMISinc]

We’re thrilled to announce Dr. Gail Farfel as our CEO. She brings more than 20 years’ experience in #neuropsychiatric clinical development & global regulatory submissions, including multiple successful #IND and #NDA apps & #FDA Advisory experience
$PMN
https://t.co/Dto4JDrAVw

[ProMIS Neurosciences @ProMISinc]

@statnews on lecanemab: "The results kick off what will be a transformational nine months for #Alzheimers research." Next-generation candidates are building on this collective knowledge and will help #ENDALZ @damiangarde @adamfeuerstein #biotech https://t.co/cJ7fyhjDYE

[ProMIS Neurosciences @ProMISinc]

@Biogen and @EisaiUS's lecanemab ushers a new era for #AlzheimersDisease. Next-generation drug candidates like PMN310 may advance this work with greater selectivity for toxic amyloid + potential for reduced side effects. #WorldAlzheimersMonth #healthcare https://t.co/5oQDiUIWeX

[ProMIS Neurosciences @ProMISinc]

Heartiest congratulations to @EisaiUS , #Biogen, its clinical trial researchers and most importantly, the clinical trial volunteers who committed their time and trust to deliver landmark news for the #Alzheimer's community. ##WorldAlzheimersMonth #ENDALZ https://t.co/1mHKWjbV4R

[ProMIS Neurosciences @ProMISinc]

PMN310 distinguishes itself from other Aß-directed antibodies by its enhanced
selectivity for toxic oligomers (negligible binding to monomers and plaque) along with its ability to withstand competition by abundant monomers $PMN #ourpromis

[ProMIS Neurosciences @ProMISinc]

Our highly selective antibodies target the toxic forms of proteins, leaving the normal forms that are essential for healthy brain and neuronal functions unaffected $PMN #exquisiteselectivity #toxicoligomers

[ProMIS Neurosciences @ProMISinc]

Dr. Gail Farfel has been appointed CEO of ProMIS Neurosciences. Dr. Farfel brings 25 years of experience and a successful track record in neurological and neuropsychiatric drug development https://t.co/ruqQeb0ciw
$PMN #CEO #alzheimersdisease #endALZ

[ProMIS Neurosciences @ProMISinc]

Our lead candidate, PMN310 for Alzheimer’s disease, selectively targets the soluble Aβ oligomers and does not bind to amyloid plaques. We expect this to reduce the risk of ARIA and potentially allow for the safe administration of higher doses $PMN

[Alzheimer's Association @alzassociation]

We are proud to support the Equity in Neuroscience & Alzheimer’s Clinical Trials (ENACT) Act! This bill would increase participation of underrepresented communities in dementia clinical trials. Learn more and take action: https://t.co/ZRQE8ElqbL. #ENACTAct #ENDALZ

[ProMIS Neurosciences @ProMISinc]

What is protein misfolding? A normal protein folds into a specific shape to perform its function. Misfolded proteins, or toxic oligomers, have a different shape which exposes toxic portions, leading to pathological mechanisms of disease and death of neurons $PMN
#stockstowatch